Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Marilena Tuffanelli"'
Autor:
Francesca Sparano, Corrado Caracò, Ester Simeone, Lucia Festino, Alfredo Budillon, Domenico Mallardo, Vito Vanella, Ernesta Cavalcanti, Paolo Ascierto, Claudia Trojaniello, Maria Grazia Vitale, Grazia D’Angelo, Marilena Tuffanelli, Sergio Arpino, Anita Minopoli, Mario Mallardo, Eleonora Cioli, Benedetta Alfano
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/9930f747cc5a44578a8c1d38f910d4e1
Autor:
Michael Bailey, Andrew White, Francesca Sparano, Alessandra Cesano, Corrado Caracò, Ester Simeone, Lucia Festino, Alfredo Budillon, Sarah Warren, Domenico Mallardo, Sarah Church, Vito Vanella, Ernesta Cavalcanti, Paolo Ascierto, Claudia Trojaniello, Maria Grazia Vitale, Margaret Ottaviano, Paolo Chiodini, Marilena Tuffanelli, Mario Fordellone, Bianca Arianna Facchini
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/88c28a6e9f0a4bd8bd85c25a054338ec
Autor:
Domenico Mallardo, Ester Simeone, Lucia Festino, Marilena Tuffanelli, Vito Vanella, Claudia Trojaniello, Maria Grazia Vitale, Margaret Ottaviano, Mariaelena Capone, Gabriele Madonna, Francesca Sparano, Eleonora Cioli, Luigi Scarpato, Marco Palla, Rossella Di Trolio, Paolo Meinardi, Corrado Caracò, Gerardo Ferrara, Paolo Muto, Ernesta Cavalcanti, Paolo Antonio Ascierto
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-6 (2023)
Abstract Background Prognostic factors for initial response of advanced cutaneous squamous cell carcinoma to cemiplimab treatment are lacking. Il-6 has been found to affect immune cell populations which impact tumor development. The aim was to invest
Externí odkaz:
https://doaj.org/article/9ccd3117e02744a0b6acca57fd56a3c0
Autor:
Costanza Maria Cristiani, Mariaelena Capone, Cinzia Garofalo, Gabriele Madonna, Domenico Mallardo, Marilena Tuffanelli, Vito Vanella, Marta Greco, Daniela Patrizia Foti, Giuseppe Viglietto, Paolo Antonio Ascierto, Hergen Spits, Ennio Carbone
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Monoclonal antibodies targeting immune checkpoints improved clinical outcome of patients with malignant melanoma. However, the mechanisms are not fully elucidated. Since immune check-point receptors are also expressed by helper innate lymphoid cells
Externí odkaz:
https://doaj.org/article/17e30316cd2d41ceb727cf6564b233c0
Autor:
Mariaelena Capone, Federica Fratangelo, Diana Giannarelli, Claudia Sorrentino, Roberta Turiello, Serena Zanotta, Domenico Galati, Gabriele Madonna, Marilena Tuffanelli, Luigi Scarpato, Antonio M. Grimaldi, Assunta Esposito, Rosa Azzaro, Antonio Pinto, Ernesta Cavalcanti, Aldo Pinto, Silvana Morello, Paolo A. Ascierto
Publikováno v:
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-10 (2020)
Abstract Background PD-1 blocking agents, such as nivolumab, have demonstrated clear anti-tumor effects and clinical benefits in a subset of patients with advanced malignancies. Nonetheless, more efforts are needed to identify reliable biomarkers for
Externí odkaz:
https://doaj.org/article/1d823bbfda724a32aa3ced2ae1f337c9
Autor:
Nicola Normanno, Andrew White, Mariaelena Capone, Gabriele Madonna, Corrado Caracò, Ester Simeone, Lucia Festino, Sarah Warren, Domenico Mallardo, Vito Vanella, Paolo Ascierto, Claudia Trojaniello, Maria Grazia Vitale, Antonio Sorrentino, Grazia D’Angelo, Marilena Tuffanelli
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/0891d08bdd5d4357bbfa5573e8c1512d
Autor:
Gabriele Madonna, Giuseppe V. Masucci, Mariaelena Capone, Domenico Mallardo, Antonio Maria Grimaldi, Ester Simeone, Vito Vanella, Lucia Festino, Marco Palla, Luigi Scarpato, Marilena Tuffanelli, Grazia D'angelo, Lisa Villabona, Isabelle Krakowski, Hanna Eriksson, Felipe Simao, Rolf Lewensohn, Paolo Antonio Ascierto
Publikováno v:
Cancers, Vol 13, Iss 16, p 4164 (2021)
The real-life application of immune checkpoint inhibitors (ICIs) may yield different outcomes compared to the benefit presented in clinical trials. For this reason, there is a need to define the group of patients that may benefit from treatment. We r
Externí odkaz:
https://doaj.org/article/e2ced8cceff045ae801eb065539ad35a
Autor:
Domenico Mallardo, Ester Simeone, Lucia Festino, Marilena Tuffanelli, Vito Vanella, Claudia Trojaniello, Maria Grazia Vitale, Margaret Ottaviano, Mariaelena Capone, Gabriele Madonna, Francesca Sparano, Eleonora Cioli, Corrado Caracò, Marco Palla, Luigi Scarpato, Rossella Di Trolio, Paolo Meinardi, Gerardo Ferrara, Paolo Muto, Ernesta Cavalcanti, Paolo Antonio Ascierto
This dataset contains data of patient characteristics and IL6 in a cohort of patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::737ed27ae7be1e1b2c8f86cacb08877c
Autor:
Paolo A. Ascierto, grazia d’angelo, Lisa Villabona, Felipe Simao, Luigi Scarpato, Gabriele Madonna, Mariaelena Capone, Ester Simeone, Vito Vanella, Isabelle Krakowski, Giuseppe Masucci, Marco Palla, Rolf Lewensohn, Lucia Festino, Antonio M. Grimaldi, Domenico Mallardo, Marilena Tuffanelli, Hanna Eriksson
Publikováno v:
Cancers, Vol 13, Iss 4164, p 4164 (2021)
Cancers
Volume 13
Issue 16
Cancers
Volume 13
Issue 16
Simple Summary Immune checkpoint inhibitors have improved the prognosis for patients with advanced melanoma. Despite the recent success of immunotherapy, many patients still do not benefit from these treatments, and their real-life application may yi
Autor:
Aldo Pinto, Silvana Morello, Diana Giannarelli, Paolo A. Ascierto, Antonio Pinto, Roberta Turiello, Serena Zanotta, Marilena Tuffanelli, Gabriele Madonna, Ernesta Cavalcanti, Mariaelena Capone, Antonio M. Grimaldi, Assunta Esposito, Rosa Azzaro, Domenico Galati, Federica Fratangelo, Claudia Sorrentino, Luigi Scarpato
Publikováno v:
Journal of Translational Medicine
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-10 (2020)
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-10 (2020)
Background PD-1 blocking agents, such as nivolumab, have demonstrated clear anti-tumor effects and clinical benefits in a subset of patients with advanced malignancies. Nonetheless, more efforts are needed to identify reliable biomarkers for outcome,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebc81a8e92424ae92b92fb5387b44324
http://hdl.handle.net/11386/4743544
http://hdl.handle.net/11386/4743544